MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

PHR.US

22.9

+0.04%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

PHR.US

22.9

+0.04%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

PHR.US

22.9

+0.04%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

PHR.US

22.9

+0.04%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

PHR.US

22.9

+0.04%↑

Search

BioMarin Pharmaceutical Inc

Closed

SectorHealthcare

53.08 1.1

Overview

Share price change

24h

Current

Min

52.07

Max

53.74

Key metrics

By Trading Economics

Income

241M

426M

Sales

80M

825M

P/E

Sector Avg

15.472

36.442

EPS

1.44

Profit margin

51.637

Employees

3,040

EBITDA

95M

319M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+87.34% upside

Dividends

By Dow Jones

Next Earnings

28 Oct 2025

Market Stats

By TradingEconomics

Market Cap

-1.5B

10B

Previous open

51.98

Previous close

53.08

News Sentiment

By Acuity

25%

75%

60 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc Chart

Past performance is not a reliable indicator of future results.

Related News

14 Oct 2025, 22:33 UTC

Earnings

America Movil 3Q Profit Jumps on Higher Revenue, Lower Financial Costs

14 Oct 2025, 22:21 UTC

Major Market Movers

Dentsply Sirona Shares Rise After SEC Probe Ends

14 Oct 2025, 19:27 UTC

Acquisitions, Mergers, Takeovers

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20 Billion

14 Oct 2025, 17:56 UTC

Major Market Movers

Nova Minerals Surges; Will Provide Minerals Briefing to Australian Government Ahead of Trump Meeting

14 Oct 2025, 23:38 UTC

Market Talk

Nikkei May Rise Amid Possible Bargain-Hunting -- Market Talk

14 Oct 2025, 22:12 UTC

Market Talk
Earnings

Fletcher Building's 1H Earnings Likely Down 16% -- Market Talk

14 Oct 2025, 21:40 UTC

Earnings

America Movil 3Q EBITDA MXN93.82B, Up 4.9% on Year >AMX.MX

14 Oct 2025, 21:39 UTC

Earnings

America Movil 3Q Rev MXN232.92B, Up 4.2% on Year >AMX.MX

14 Oct 2025, 21:38 UTC

Earnings

America Movil 3Q Net MXN22.7B Vs. Net MXN6.43B Year Ago >AMX.MX

14 Oct 2025, 21:06 UTC

Earnings

These Stocks Moved the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14 Oct 2025, 20:50 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

14 Oct 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 Oct 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

14 Oct 2025, 20:50 UTC

Market Talk
Earnings

Health Care Roundup: Market Talk

14 Oct 2025, 20:13 UTC

Earnings

BlackRock's Assets Hit Record $13.5 Trillion After Market Rally, Dealmaking Spree -- 2nd Update

14 Oct 2025, 20:01 UTC

Earnings

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 5th Update

14 Oct 2025, 19:21 UTC

Market Talk
Earnings

Citigroup's Higher Outlook Leaves Questions -- Market Talk

14 Oct 2025, 19:12 UTC

Acquisitions, Mergers, Takeovers

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20B

14 Oct 2025, 19:08 UTC

Market Talk

Oil Futures Settle Lower on Trade, Oversupply Concerns -- Market Talk

14 Oct 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Falls as Weather Outlook Stays Mild -- Market Talk

14 Oct 2025, 18:59 UTC

Acquisitions, Mergers, Takeovers

Bouygues Telecom, Free-iliad Group, Orange Bid for Corresponds to Total Enterprise Value of EUR17B for Altice France Assets

14 Oct 2025, 18:58 UTC

Acquisitions, Mergers, Takeovers

Bouygues Telecom, Free-iliad Group, Orange Bid Excludes Stakes in Intelcia, UltraEdge, XP Fibre, Altice Technical Services

14 Oct 2025, 18:58 UTC

Acquisitions, Mergers, Takeovers

Bouygues Telecom, Free-iliad Group, Orange Bid Covers Most SFR Assets

14 Oct 2025, 18:56 UTC

Acquisitions, Mergers, Takeovers

Bouygues Telecom, Free-iliad Group, Orange Submit Joint Non-Binding Offer to Buy Large Part of Altice's Activities in France

14 Oct 2025, 18:46 UTC

Earnings

These Stocks Are Moving the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14 Oct 2025, 18:04 UTC

Earnings

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 4th Update

14 Oct 2025, 18:01 UTC

Market Talk

Gold Finds Another Record as Traders Eye Further Upside -- Market Talk

14 Oct 2025, 17:54 UTC

Earnings

Salesforce's Dreamforce Conference Kicks Off. CEO Benioff Touts AI Tool Agentforce. -- Barrons.com

14 Oct 2025, 17:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 Oct 2025, 17:50 UTC

Market Talk

Lower Dollar Provides Some Strength in Grains -- Market Talk

Peer Comparison

Price change

BioMarin Pharmaceutical Inc Forecast

Price Target

By TipRanks

87.34% upside

12 Months Forecast

Average 98.26 USD  87.34%

High 122 USD

Low 60 USD

Based on 22 Wall Street analysts offering 12 month price targets forBioMarin Pharmaceutical Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

22 ratings

18

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

59.405 / 62.19Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

60 / 371 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat